Parametric Portfolio Associates LLC reduced its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 6.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,070 shares of the life sciences company’s stock after selling 11,466 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Integra Lifesciences were worth $8,752,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IART. Oregon Public Employees Retirement Fund raised its position in Integra Lifesciences by 4,410.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 1,226,245 shares in the last quarter. Brown Advisory Inc. bought a new stake in Integra Lifesciences during the fourth quarter worth $45,653,000. Norges Bank bought a new stake in Integra Lifesciences during the fourth quarter worth $32,141,000. Janus Henderson Group PLC raised its position in Integra Lifesciences by 31.5% during the first quarter. Janus Henderson Group PLC now owns 2,873,324 shares of the life sciences company’s stock worth $160,102,000 after acquiring an additional 688,761 shares in the last quarter. Finally, BlackRock Inc. raised its position in Integra Lifesciences by 3.2% during the fourth quarter. BlackRock Inc. now owns 6,730,304 shares of the life sciences company’s stock worth $303,536,000 after acquiring an additional 210,960 shares in the last quarter. 82.27% of the stock is currently owned by hedge funds and other institutional investors.

In other Integra Lifesciences news, Director Christian S. Schade sold 15,658 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $51.56, for a total value of $807,326.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.50% of the stock is owned by insiders.

IART has been the topic of several analyst reports. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Monday, February 18th. BidaskClub raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $50.00 price target on shares of Integra Lifesciences in a research report on Thursday, February 21st. Morgan Stanley set a $57.00 price target on shares of Integra Lifesciences and gave the stock a “hold” rating in a research report on Friday, February 22nd. Finally, JMP Securities reaffirmed a “buy” rating and set a $62.00 price target on shares of Integra Lifesciences in a research report on Wednesday, February 27th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. Integra Lifesciences has an average rating of “Hold” and a consensus price target of $58.00.

NASDAQ:IART opened at $50.88 on Friday. Integra Lifesciences Holdings Corp has a one year low of $42.14 and a one year high of $67.50. The firm has a market capitalization of $4.35 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 1.47 and a beta of 0.97. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.86 and a current ratio of 2.86.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The firm had revenue of $359.69 million for the quarter, compared to the consensus estimate of $361.12 million. During the same period in the previous year, the company earned $0.58 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. On average, analysts predict that Integra Lifesciences Holdings Corp will post 2.7 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dailypolitical.com/2019/06/16/parametric-portfolio-associates-llc-has-8-75-million-holdings-in-integra-lifesciences-holdings-corp-nasdaqiart.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.